Literature DB >> 6253403

Variations in the contribution of induced interferon and adjuvanticity to the antiviral effect of different polyinosinic acid . polycytidylic acid formulations in mice infected with encephalomyocarditis virus.

N Stebbing, I J Lindley, K M Dawson.   

Abstract

Treatment of mice with polyinosinic acid . polycytidylic acid [poly(I) . poly(C)] 6 h before infection and once daily on days 1, 2, 3, 4, 7, and 10 after infection with encephalomyocarditis virus was found to confer no additional protection as compared with a single treatment 6 h before infection. When complexed with a colloid formed between carboxymethylcellulose and polylysine, poly(I) . poly(C) conferred significant additional protection with the multiple treatment regimen compared with a single treatment of 6 h before infection. The additional antiviral activity of multiple treatments could not be entirely attributed to interferon induction by the complexed form of poly(I) . poly(C), because free and complexed poly(I) . poly(C) both caused hyporesponsiveness to interferon induction after multiple treatments. However, mice protected against encephalomyocarditis virus infection by multiple treatments with the colloidal complex form of poly(I) . poly(C) showed a significant increase in resistance to reinfection, and this was attributable to adjuvant effects of the colloidal complex form of poly(I) . poly(C). The contribution of interferon induction and adjuvanticity of the poly(I) . poly(C) formulations varied with the times of treatment relative to infection, the dose of polynucleotide material, and the virus dose.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6253403      PMCID: PMC551224          DOI: 10.1128/iai.29.3.960-965.1980

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  12 in total

1.  Naturally occurring double-stranded RNA and immune responses. Effects on plaque-forming cells and antibody formation.

Authors:  P G Cunnington; J D Naysmith
Journal:  Immunology       Date:  1975-03       Impact factor: 7.397

2.  Requirement for macrophages for interferon to be effective against encephalomyocarditis virus infection of mice.

Authors:  N Stebbing; K M Dawson; I J Lindley
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

3.  Mechanism of antiviral activity in vivo of polycarboxylases which induce interferon production.

Authors:  A Billiau; J J Muyembe; P De Somer
Journal:  Nat New Biol       Date:  1971-08-11

4.  Anti-viral activity of single-stranded homopolynucleotides against encephalomyocarditis virus and Semliki Forest virus in adult mice without interferon induction.

Authors:  N Stebbing; C A Grantham; N H Carey
Journal:  J Gen Virol       Date:  1976-01       Impact factor: 3.891

5.  Modified polyriboinosinic-polyribocytidylic acid, an immunological adjuvant.

Authors:  W E Houston; C L Crabbs; E L Stephen; H B Levy
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

6.  A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates.

Authors:  H B Levy; G Baer; S Baron; C E Buckler; C J Gibbs; M J Iadarola; W T London; J Rice
Journal:  J Infect Dis       Date:  1975-10       Impact factor: 5.226

7.  Interferon induction in cynomolgus and rhesus monkey after repeated doses of a modified polyriboinosinic-polyribocytidylic acid complex.

Authors:  M L Sammons; E L Stephen; H B Levy; S Baron; D E Hilmas
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

8.  Swine influenza virus vaccine: potentiation of antibody responses in rhesus monkeys.

Authors:  E L Stephen; D E Hilmas; J A Mangiafico; H B Levy
Journal:  Science       Date:  1977-09-23       Impact factor: 47.728

9.  Prophylactic control of simian hemorrhagic fever in monkeys by an interferon inducer, polyriboinosinic-polyribocytidylic acid-poly-L-lysine.

Authors:  H B Levy; W London; D A Fuccillo; S Baron; J Rice
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

10.  Modification of chronic hepatitis-B virus infection in chimpanzees by administration of an interferon inducer.

Authors:  R H Purcell; W T London; V J McAuliffe; A E Palmer; P M Kaplan; J L Gerin; J Wagner; H Popper; E Lvovsky; D C Wong; H B Levy
Journal:  Lancet       Date:  1976-10-09       Impact factor: 79.321

View more
  3 in total

1.  Antiherpetic effects of a human alpha interferon analog, IFN-alpha Con1, in hamsters.

Authors:  E N Fish; K Banerjee; H L Levine; N Stebbing
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

2.  Antiviral activity of bacteria-derived human alpha interferons against encephalomyocarditis virus infection of mice.

Authors:  P K Weck; E Rinderknecht; D A Estell; N Stebbing
Journal:  Infect Immun       Date:  1982-02       Impact factor: 3.441

3.  Protectivity of herpes simplex virus antigens: studies in mice on the adjuvant effect of PICLC and on the dependence of protection on T cell competence.

Authors:  J Hilfenhaus; H Christ; R Köhler; H Moser; H Kirchner; H B Levy
Journal:  Med Microbiol Immunol       Date:  1981       Impact factor: 3.402

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.